Sunday, 22 November 2026

Novo Nordisk Sues Hims & Hers Over $49 Weight-Loss Pill Copycat

BT Business Desk
Disclosure : 09 Feb 2026, 11:22 PM Update : 09 Feb 2026, 11:23 PM
Novo Nordisk filed the lawsuit on February 9, 2026, alleging that Hims & Hers infringed on its semaglutide patents (valid until 2032).
Novo Nordisk filed the lawsuit on February 9, 2026, alleging that Hims & Hers infringed on its semaglutide patents (valid until 2032).

Novo Nordisk has filed a patent infringement lawsuit against telehealth provider Hims & Hers, marking a major escalation in the battle over cheap, unapproved versions of popular weight-loss drugs.

The move comes after Hims launched—and then quickly withdrew—a $49 monthly version of Novo's new Wegovy pill. Despite the withdrawal, Novo is seeking a permanent ban on Hims selling any compounded versions of its patented drug, semaglutide.

The legal action and a simultaneous crackdown by the U.S. Food and Drug Administration (FDA) sent shockwaves through the market on Monday: Novo Nordisk shares jumped nearly 6%. Hims & Hers stock plunged 25%. Eli Lilly, a chief rival, saw its shares rise as the FDA's stance signaled a broader "war" on unregulated copycat medications.

Novo Nordisk's general counsel, John Kuckelman, described the launch of the Hims pill as a "tipping point," stating that the industry has seen enough of unauthorized mass-compounding in the U.S. market.

"Big Pharma" vs. Patient Access Hims & Hers responded by calling the lawsuit a "blatant attack" on millions of Americans who rely on affordable, compounded medications. The firm accused "Big Pharma" of weaponizing the courts to limit consumer choice and protect high profit margins.

While U.S. law allows pharmacies to mix custom doses during drug shortages, the FDA warned on Friday that it would restrict the ingredients used in these knock-offs due to safety concerns.

The fight for dominance is intensifying as the market moves toward oral treatments: Novo's Wegovy Pill: Recently launched with a $149 monthly price tag via the new TrumpRx discount site.

Lilly’s Contender: Eli Lilly expects FDA approval for its own weight-loss pill, orforglipron, by April 2026.

As competition grows, the outcome of this lawsuit could decide whether the future of weight-loss medicine belongs to the original patent holders or cheaper telehealth alternatives.

  • Latest

  • Popular

Garment sector loses $428 million in 18 days: BGMEA

1

NCP Sets Conditions for Prime Minister’s National Unity Call

2

Nine More Die With Measles Symptoms in Bangladesh

3

Police Inspector Dies of Dengue in Jhalokathi

4

Thirteen of Nazrul University’s 25 Departments Have no Professors

5

Hazlewood Says He Was Never Close to Khawaja, Bears No Resentment Over Book

6

At Least 14 Missing After Russian Drone Hits Kyiv Apartment Building

7

US - Iran War / Israel and US Plans for Possible Joint Attack on Iran

8

Govt Plans 25,000 New SME Entrepreneurs in Four Years: Prime Minister

9

Seven Dead and 50 Missing After Indonesia Factory Fire

10

High Court Orders Policy to Regulate Social Media Use by Under-16s

11

Blast Hits Ammunition Depot at Libya’s Benghazi Naval Base

12

Jubo League Leader Papia Sultana Arrested in Dhaka Over Narail ‘Sabotage Plot’

13

Prime Minister Inaugurates 13th National SME Products Fair-2026

14

Toxic Liquor Kills 16 and Leaves 600 Hospitalised in India’s Manipur

15

Premier League / Man City Held by Fulham, Chelsea Thrashed by Leeds, Arsenal Draw

16

Ukraine Russia War / Russian Cargo Ship Catches Fire After Drone Strike in Gulf of Finland

17

Gold Prices Plunge by Tk 17,146 in Bangladesh in Two Days

18

Unity Will Prevent Bangladesh from Becoming a Subservient State: PM

19

5 people die of measles and dengue in a day in the country

20